271 related articles for article (PubMed ID: 15795539)
21. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Frelinger AL; Michelson AD; Wiviott SD; Trenk D; Neumann FJ; Miller DL; Jakubowski JA; Costigan TM; McCabe CH; Antman EM; Braunwald E
Thromb Haemost; 2011 Aug; 106(2):219-26. PubMed ID: 21713327
[TBL] [Abstract][Full Text] [Related]
22. P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.
Zoheir N; Abd Elhamid S; Abulata N; El Sobky M; Khafagy D; Mostafa A
Blood Coagul Fibrinolysis; 2013 Jul; 24(5):525-31. PubMed ID: 23751603
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
[TBL] [Abstract][Full Text] [Related]
24. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease.
Matsagas M; Jagroop IA; Geroulakos G; Mikhailidis DP
Clin Appl Thromb Hemost; 2003 Apr; 9(2):115-20. PubMed ID: 12812379
[TBL] [Abstract][Full Text] [Related]
25. Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
Nührenberg TG; Stratz C; Leggewie S; Hochholzer W; Valina CM; Gick M; Kirtane AJ; Stone GW; Neumann FJ; Trenk D
Thromb Haemost; 2015 Nov; 114(5):1020-7. PubMed ID: 26305340
[TBL] [Abstract][Full Text] [Related]
26. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
[TBL] [Abstract][Full Text] [Related]
27. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.
Bonello L; Bonello-Palot N; Armero S; Bonello C; Mokhtar OA; Arques S; Dignat-George F; Camoin-Jau L; Paganelli F
Thromb Res; 2010 Apr; 125(4):e167-70. PubMed ID: 19914687
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.
Lev EI; Patel RT; Guthikonda S; Lopez D; Bray PF; Kleiman NS
Thromb Res; 2007; 119(3):355-60. PubMed ID: 16581111
[TBL] [Abstract][Full Text] [Related]
29. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
[TBL] [Abstract][Full Text] [Related]
30. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
[TBL] [Abstract][Full Text] [Related]
31. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.
Claeys MJ; Van Der Planken MG; Michiels JJ; Vertessen F; Dilling D; Bosmans JM; Vrints CJ
Blood Coagul Fibrinolysis; 2002 Jun; 13(4):283-8. PubMed ID: 12032392
[TBL] [Abstract][Full Text] [Related]
32. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
Smith SM; Judge HM; Peters G; Armstrong M; Fontana P; Gaussem P; Daly ME; Storey RF
Platelets; 2006 Jun; 17(4):250-8. PubMed ID: 16769602
[TBL] [Abstract][Full Text] [Related]
33. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
[TBL] [Abstract][Full Text] [Related]
34. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
Storey RF; Judge HM; Wilcox RG; Heptinstall S
Thromb Haemost; 2002 Sep; 88(3):488-94. PubMed ID: 12353080
[TBL] [Abstract][Full Text] [Related]
36. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
37. Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.
Oestreich JH; Holt J; Dunn SP; Smyth SS; Campbell CL; Charnigo R; Akers WS; Steinhubl SR
Coron Artery Dis; 2009 May; 20(3):207-13. PubMed ID: 19318928
[TBL] [Abstract][Full Text] [Related]
38. Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention.
Yao Y; Tang XF; Zhang JH; He C; Ma YL; Xu JJ; Song Y; Liu R; Meng XM; Song L; Chen J; Wang M; Xu B; Gao RL; Yuan JQ
Thromb Res; 2016 May; 141():28-34. PubMed ID: 26962983
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Behan MW; Fox SC; Heptinstall S; Storey RF
Platelets; 2005 Mar; 16(2):73-80. PubMed ID: 15823862
[TBL] [Abstract][Full Text] [Related]
40. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
